EGFR-IN-31 is a potent EGFR inhibitor with potential for the investigation of EGFR mutation-related diseases, particularly non-small cell lung cancer (NSCLC), as overexpression and mutations of epidermal growth factor receptor (EGFR) are clearly associated with uncontrolled cell proliferation and the progression of most cancers.